This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will Agenus Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Agenus.
Are You Looking for a Top Momentum Pick? Why Agenus (AGEN) is a Great Choice
by Zacks Equity Research
Does Agenus (AGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss and beats sales estimates in the third quarter of 2019.
Agenus (AGEN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 13.16% and 27.82%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Agenus (AGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) reports wider-than-expected loss and beats sales estimates in the second quarter of 2019.
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -15.15% and 192.92%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Agenus (AGEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
by Zacks Equity Research
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
by Zacks Equity Research
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
by Zacks Equity Research
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Agenus (AGEN) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
by Zacks Equity Research
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
by Zacks Equity Research
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
Gilead & Galapagos Announce Positive Data on Arthritis Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce positive results from late-stage studies on investigational drug, filgotinib for the treatment of RA.
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
by Zacks Equity Research
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of -42.86% and -19.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
by Zacks Equity Research
Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
Gilead (GILD) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
A mixed fourth-quarter for biotech bigwig Gilead as it misses on earnings but beat on revenues.
Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales?
by Zacks Equity Research
Gilead (GILD) is scheduled to report fourth-quarter results on Feb 4. Investors will likely focus on the strong HIV franchise and other pipeline updates.